Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target

Barclays analyst Jenna Davidner upgraded Phathom Pharmaceuticals (NASDAQ:PHAT) to Overweight from Equal Weight and raised her price target to $18 from $16, a $2 increase (12.5%). The action is a modestly positive analyst signal that could support near-term share performance but is unlikely to drive broad market moves. Impact is company-specific and should be weighed alongside other fundamental catalysts.

Analysis

Barclays analyst Jenna Davidner upgraded Phathom Pharmaceuticals (NASDAQ:PHAT) to Overweight from Equal Weight and raised her price target to $18 from $16, a $2 increase (12.5%). The action is a modestly positive analyst signal that could support near-term share performance but is unlikely to drive broad market moves. Impact is company-specific and should be weighed alongside other fundamental catalysts.